Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anti-tuberculosis peptide therapeutics - Linnane Pharma

Drug Profile

Research programme: anti-tuberculosis peptide therapeutics - Linnane Pharma

Latest Information Update: 03 Feb 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Linnane Pharma
  • Class Antituberculars; Peptides
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Tuberculosis

Most Recent Events

  • 04 Jan 2023 Preclinical trials in Tuberculosis in Sweden (unspecified route) as of January 2023 (Linnane Pharma pipeline, January 2023)
  • 04 Jan 2023 Pharmacodynamics data from preclinical trial in Tuberculosis released by Linnane Pharma prior to January 2023
  • 28 Jul 2022 Linnane Pharma has patent protection for peptides with antibiotic potential against Mycobacterium tuberculosis in the USA, Australia and Europe and patent pending in Canada
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top